結核治療薬の市場規模、シェア、動向分析レポート：疾患タイプ別（活動性結核、潜在性結核）、治療法別、投与経路別、剤形別、流通チャネル別、地域別、セグメント別予測、2023～2030年

結核治療薬市場の成長と動向

Grand View Research, Inc.の新しいレポートによると、世界の結核治療薬市場規模は、2023年から2030年にかけて5.09%のCAGRで拡大し、29億9000万米ドルに達すると予想されています、結核治療薬の需要は、結核の有病率が上昇していることに起因しているとのことです。

世界保健機関の2022年世界結核報告書によると、2021年には推定1060万人が罹患し、2020年から4.5％増加し、約160万人の死亡を占めています。この高い死亡率は、市場における費用対効果に優れた効率的な薬剤のアンメットニーズを実証しています。

薬剤耐性結核（DR-TB）の負担は2020年から2021年にかけて3％増加し、2021年にはリファンピシン耐性結核の新規患者が45万人発生しました。これは、結核やDR-TBに苦しむ人々の増加が報告された過去数年では初めてのことです。2021年のCOVID-19パンデミックは、結核医療を含む多くのサービスを混乱させました。しかし、その影響は結核対応に深刻に表れています。さらに、BCGと呼ばれる現在のワクチンは100年以上前のものであり、成人での効果も限定的であるため、感染を抑制する力は限られています。したがって、治療薬のビジネスチャンスが生まれています。

多剤耐性および広範囲薬剤耐性結核の発生率の上昇は、適切な治療薬の提供に対する需要をさらに促進しています。2022年12月、WHOは、薬剤耐性結核の治療に関する大きな改善を特徴とする最新の統合ガイドラインを発表しました。本ガイドラインでは、MDR/RR-TB患者に対する治療法として、プレトマニド、ベダキリン、モキシフロキサシン、リネゾリドからなる新しい経口6カ月レジメン（BPaLM）をまとめ、使用を推奨しています。BPaLMレジメンは、治療期間を短縮し、より良い治療結果をもたらすと期待されています。

さらに、主要な企業は、新規の結核治療薬を開発し、市場競争力を維持するために、共同研究やパートナーシップに力を入れています。例えば、2021年7月、結核治療薬を進歩させるために、13カ国から30人のパートナーからなる新しいコンソーシアムが正式に発足しました。このプロジェクトはUNITE4TBであり、治療薬の加速と改善を目標に、約1億9800万米ドルを投資する7年計画となっています。さらに、インドでは2025年末までに結核を撲滅し、対象とすることを意図して、2022年9月に発足したNi-kshay Mitraのようなイニシアチブが登場しています。

結核治療薬市場レポートハイライト。

• 2022年には活動性結核のセグメントがエトを支配し、これは有病率と再発の増加に起因します。
• 第二選択治療薬分野は、需要の増加と新しい第二選択治療薬開発のための研究開発の高まりにより、予測期間中に最も速い成長率を示すと予想されます。
• 2022年は、錠剤の形で多くの薬剤が入手可能であることから、経口剤が市場を独占しています。
• COVID-19のパンデミックは、治療薬への資金提供の減少や病気の診断率の低下により、市場に悪影響を与えました。
• 2022年、MEAが最大の市場シェアを獲得。これは、疾患の早期診断に向けた取り組みが強化され、治療法の普及率が向上したことに起因します。

目次

第1章 結核治療薬市場：調査手法と範囲

• 市場セグメンテーション
  • セグメントの範囲
  • 地域範囲
• 調査手法
• 情報調達
  • 購入したデータベース
  • Gvrの内部データベース
  • 二次情報
  • 1次調査
  • 1次調査の詳細
• 情報またはデータ分析
  • データ分析モデル
• 市場の策定と検証
• モデルの詳細
  • コモディティフロー分析
    • アプローチ1：コモディティフローアプローチ
    • アプローチ2：ボトムアップアプローチを使用した国ごとの市場予測
    • アプローチ2：トップダウンアプローチを使用した国ごとの市場推定
• 世界市場：CAGR計算
• 二次情報のリスト
• 目的
• 略語一覧

第2章 結核治療薬市場：エグゼクティブサマリー

• 市場のスナップショット
• セグメントのスナップショット
• 競合情勢のスナップショット

第3章 結核治療薬市場：業界の見通し

• 市場系列の見通し
  • 親市場系統の見通し
  • 関連/補助的な市場の見通し
• 浸透と成長の見通しのマッピング
• 市場力学
  • 市場促進要因
    • 結核の有病率の上昇
    • ヘルスケアインフラへの投資の増加
    • 高齢者人口の増加
  • 市場抑制要因分析
    • 多剤耐性結核の高コスト
    • 抗結核薬に関連する副作用
• SWOT分析、要因別（政治と法律、経済と技術）
• 業界分析- ポーターズ
• 償還と規制のシナリオ
• 主要取引と戦略的提携
  • 新製品の発売
  • 取得
  • 拡張
  • パートナーシップ
  • マーケティングとプロモーション

第4章 結核治療薬市場：競合情勢

• 最近の進展・影響分析：主要市場参入企業別
  • アンゾフマトリックス
• 企業分類
  • イノベーター
    • 市場の差別化要因
• ベンダー情勢
  • 主要なディストリビューターとチャネルパートナーのリスト
  • 主要顧客
  • 主要企業の市場シェア分析、2022年
• 公開企業
  • 競合ダッシュボード分析
• 非公開企業
  • 主要な新興企業のリスト
• 地域ネットワークマップ

第5章 結核治療薬市場：疾患タイプのビジネス分析

• 定義と範囲
• 疾患タイプの市場シェア分析、2022年および2030年
• 2018年から2030年までの疾患タイプ別の世界の結核治療薬市場
• 結核治療薬市場：疾患タイプの変動分析
• 活動性結核
• 潜在性結核

第6章 結核治療薬市場：治療ビジネス分析

• 定義と範囲
• 治療市場シェア分析、2022年および2030年
• 世界の結核治療薬市場、治療別、2018年から2030年
• 結核治療市場：治療変動分析
• 一次治療
• 二次治療

第7章 結核治療薬市場：投与経路ビジネス分析

• 定義と範囲
• 投与経路の市場シェア分析、2022年および2030年
• 世界の結核治療薬市場、投与経路別、2018年から2030年
• 結核治療市場：投与経路の変動分析
• オーラル
• 親の
• その他

第8章 結核治療薬市場：剤形ビジネス分析

• 定義と範囲
• 剤形市場シェア分析、2022年および2030年
• 世界の結核治療薬市場、剤形別、2018年から2030年
• 結核治療薬市場：剤形変動分析
• 錠剤
• カプセル
• 注射
• その他

第9章 結核治療薬市場：流通チャネルのビジネス分析

• 定義と範囲
• 流通チャネルの市場シェア分析、2022年および2030年
• 世界の結核治療薬市場、流通チャネル別、2018年から2030年
• 結核治療薬市場：流通チャネルの変動分析
• 病院薬局
• 小売薬局
• オンライン薬局
• その他

第10章 結核治療薬市場：地域ビジネス分析

• 定義と範囲
• 地域市場シェア分析、2022年および2030年
• 地域市場ダッシュボード
• 地域市場のスナップショット
• SWOT分析、要因別（政治と法律、経済と技術）
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • メア
• 市場規模、予測、トレンド分析、2022年から2030年
• 北米
  • 米国
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 輸出入シナリオ
    • 投資シナリオ
  • カナダ
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 輸出入シナリオ
    • 投資シナリオ
• 欧州
  • 英国
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 輸出入シナリオ
    • 投資シナリオ
  • ドイツ
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 輸出入シナリオ
    • 投資シナリオ
  • スペイン
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 輸出入シナリオ
    • 投資シナリオ
  • フランス
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 輸出入シナリオ
    • 投資シナリオ
  • イタリア
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 輸出入シナリオ
    • 投資シナリオ
  • ロシア
    • 規制の枠組み
    • 競合シナリオ
    • 輸出入シナリオ
    • 投資シナリオ
  • デンマーク
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 輸出入シナリオ
    • 投資シナリオ
  • スウェーデン
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 輸出入シナリオ
    • 投資シナリオ
  • ノルウェー
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 輸出入シナリオ
    • 投資シナリオ
• アジア太平洋地域
  • 日本
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 輸出入シナリオ
    • 投資シナリオ
  • 中国
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 輸出入シナリオ
    • 投資シナリオ
  • インド
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 輸出入シナリオ
    • 投資シナリオ
  • 韓国
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 輸出入シナリオ
    • 投資シナリオ
  • タイ
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 輸出入シナリオ
    • 投資シナリオ
  • オーストラリア
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 輸出入シナリオ
    • 投資シナリオ
• ラテンアメリカ
  • ブラジル
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 輸出入シナリオ
    • 投資シナリオ
  • メキシコ
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 輸出入シナリオ
    • 投資シナリオ
  • アルゼンチン
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 輸出入シナリオ
    • 投資シナリオ
• MEA
  • 南アフリカ
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 輸出入シナリオ
    • 投資シナリオ
  • サウジアラビア
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 輸出入シナリオ
    • 投資シナリオ
  • アラブ首長国連邦
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 輸出入シナリオ
    • 投資シナリオ
  • クウェート
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 輸出入シナリオ
    • 投資シナリオ

第11章 結核治療薬市場：企業プロファイリング

• 企業プロファイル
  • Astrazeneca
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Johnson &Johnson Services, Inc.
    • 会社概要
  • 2.Financial Performance
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Eli Lilly And Company
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • F. Hoffmann-La Roche Ltd.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Viatris Inc.（Mylan NV）
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Teva Pharmaceutical Industries, Ltd.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Sanofi
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Novartis Ag
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Sun Pharmaceutical Industries Ltd.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Pfizer Inc.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviation
• Table 3 Incidence of Diseases
• Table 4 Global Tuberculosis Therapeutics Market, By Region, 2018 - 2030 (USD Million)
• Table 5 Global Tuberculosis Therapeutics Market, By Drug type, 2018 - 2030 (USD Million)
• Table 6 North America Tuberculosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 7 North America Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 8 North America Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 9 North America Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 10 North America Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 11 North America Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 12 U.S. Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 13 U.S. Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 14 U.S. Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 15 U.S. Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 16 U.S. Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 17 Canada Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 18 Canada Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 19 Canada Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 20 Canada Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 21 Canada Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 22 Europe Tuberculosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 23 Europe Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 24 Europe Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 25 Europe Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 26 Europe Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 27 Europe Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 28 Germany Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 29 Germany Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 30 Germany Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 31 Germany Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 32 Germany Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 33 U.K. Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 34 U.K. Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 35 U.K. Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 36 U.K. Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 37 U.K. Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 38 France Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 39 France Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 40 France Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 41 France Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 42 France Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 43 Italy Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 44 Italy Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 45 Italy Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 46 Italy Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 47 Italy Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 48 Spain Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 49 Spain Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 50 Spain Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 51 Spain Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 52 Spain Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 53 Denmark Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 54 Denmark Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 55 Denmark Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 56 Denmark Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 57 Denmark Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 58 Sweden Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 59 Sweden Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 60 Sweden Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 61 Sweden Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 62 Sweden Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 63 Norway Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 64 Norway Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 65 Norway Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 66 Norway Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 67 Norway Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 68 Asia Pacific Tuberculosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 69 Asia Pacific Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 70 Asia Pacific Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 71 Asia Pacific Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 72 Asia Pacific Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 73 Asia Pacific Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 74 Japan Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 75 Japan Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 76 Japan Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 77 Japan Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 78 Japan Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 79 China Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 80 China Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 81 China Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 82 China Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 83 China Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 84 India Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 85 India Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 86 India Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 87 India Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 88 India Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 89 South Korea Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 90 South Korea Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 91 South Korea Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 92 South Korea Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 93 South Korea Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 94 Australia Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 95 Australia Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 96 Australia Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 97 Australia Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 98 Australia Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 99 Thailand Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 100 Thailand Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 101 Thailand Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 102 Thailand Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 103 Thailand Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 104 Latin America Tuberculosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 105 Latin America Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 106 Latin America Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 107 Latin America Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 108 Latin America Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 109 Latin America Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 110 Brazil Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 111 Brazil Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 112 Brazil Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 113 Brazil Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 114 Brazil Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 115 Mexico Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 116 Mexico Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 117 Mexico Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 118 Mexico Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 119 Mexico Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 120 Argentina Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 121 Argentina Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 122 Argentina Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 123 Argentina Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 124 Argentina Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 125 Middle East & Africa Tuberculosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 126 Middle East & Africa Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 127 Middle East & Africa Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 128 Middle East & Africa Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 129 Middle East & Africa Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 130 Middle East & Africa Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 131 Saudi Arabia Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 132 Saudi Arabia Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 133 Saudi Arabia Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 134 Saudi Arabia Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 135 Saudi Arabia Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 136 South Africa Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 137 South Africa Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 138 South Africa Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 139 South Africa Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 140 South Africa Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 141 UAE Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 142 UAE Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 143 UAE Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 144 UAE Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 145 UAE Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 146 Kuwait Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 147 Kuwait Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 148 Kuwait Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 149 Kuwait Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 150 Kuwait Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market Research Process
• Fig. 2 Information Procurement
• Fig. 3 Primary Research Pattern
• Fig. 4 Market Research Approaches
• Fig. 5 Value Chain-Based Sizing & Forecasting
• Fig. 6 Market Formulation & Validation
• Fig. 7 Tuberculosis Therapeutics Market Segmentation
• Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
• Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
• Fig. 11 Penetration & Growth Prospect Mapping
• Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 13 Porter's Five Forces Analysis
• Fig. 14 Market Penetration & Growth Prospect Mapping
• Fig. 15 Tuberculosis therapeutics market: Disease type outlook and key takeaways
• Fig. 16 Tuberculosis therapeutics market: Disease type movement analysis & market share 2022 & 2030
• Fig. 17 Active TB market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 18 Latent TB market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 19 Tuberculosis therapeutics market: Therapy outlook and key takeaways
• Fig. 20 Tuberculosis therapeutics market: Therapy movement analysis & market share 2022 & 2030
• Fig. 21 First-line therapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Second-line therapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Tuberculosis therapeutics market: Route of administration outlook and key takeaways
• Fig. 24 Tuberculosis therapeutics market: Route of administration movement analysis & market share 2022 & 2030
• Fig. 25 Oral market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 Parenteral market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 Tuberculosis therapeutics market: Dosage form outlook and key takeaways
• Fig. 29 Tuberculosis therapeutics market: Dosage form movement analysis & market share 2022 & 2030
• Fig. 30 Tablets market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Capsules market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 Injections market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 33 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 34 Tuberculosis therapeutics market: Distribution channel outlook and key takeaways
• Fig. 35 Tuberculosis therapeutics market: Distribution channel movement analysis & market share 2022 & 2030
• Fig. 36 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 38 Online pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 39 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 40 Regional Marketplace: Key Takeaways
• Fig. 41 Regional Outlook, 2022 & 2030
• Fig. 42 Regional Market Dashboard
• Fig. 43 Regional Market Place: Key Takeaways
• Fig. 44 North America, SWOT Analysis
• Fig. 45 Europe, SWOT Analysis
• Fig. 46 Asia Pacific, SWOT Analysis
• Fig. 47 Latin America, SWOT Analysis
• Fig. 48 MEA, SWOT Analysis
• Fig. 49 North America
• Fig. 50 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 51 U.S.
• Fig. 52 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 53 Canada
• Fig. 54 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 55 Europe
• Fig. 56 Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 57 U.K.
• Fig. 58 U.K. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 59 Germany
• Fig. 60 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 61 France
• Fig. 62 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 63 Italy
• Fig. 64 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 65 Spain
• Fig. 66 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 67 Denmark
• Fig. 68 Denmark Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 69 Sweden
• Fig. 70 Sweden Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 71 Norway
• Fig. 72 Norway Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 73 Asia Pacific
• Fig. 74 Asia-Pacific Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 75 Japan
• Fig. 76 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 77 China
• Fig. 78 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 79 India
• Fig. 80 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 81 Australia
• Fig. 82 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 83 Thailand
• Fig. 84 Thailand Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 85 South Korea
• Fig. 86 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 87 Latin America
• Fig. 88 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 89 Brazil
• Fig. 90 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 91 Mexico
• Fig. 92 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 93 Argentina
• Fig. 94 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 95 MEA
• Fig. 96 MEA Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 97 South Africa
• Fig. 98 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 99 Saudi Arabia
• Fig. 100 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 101 UAE
• Fig. 102 UAE Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 103 Kuwait
• Fig. 104 Kuwait Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 105 Strategy Mapping

Tuberculosis Therapeutics Market Growth & Trends:

The global tuberculosis therapeutics market size is expected to reach USD 2.99 billion, expanding at a CAGR of 5.09% from 2023 to 2030, according to a new report by Grand View Research, Inc., The demand for TB therapeutics is attributable to the rising prevalence of tuberculosis. According to the World Health Organization's 2022 Global TB report, an estimated 10.6 million people suffered in 2021, a 4.5% increase from 2020, and has accounted for the death of around 1.6 million people. This high rate of mortality demonstrates an unmet need for cost-effective and efficient drugs in the market.

The burden of drug-resistant tuberculosis (DR-TB) increased by 3% between 2020 and 2021, with 450 000 new cases of rifampicin-resistant tuberculosis in 2021. This is the first time in past few years that an increase in the number of people suffering from TB and DR-TB has been reported. The COVID-19 pandemic in 2021 has disrupted many services, including TB care. However, the impact has been severely seen in the TB response. Moreover, because the current vaccine, known as BCG, is over 100 years old and has limited efficacy in adults, the ability to control transmission is limited. Thus, creating business opportunity for therapeutics.

The rising incidence of multidrug-resistant and extensively drug-resistant tuberculosis has further propelled the demand for providing appropriate therapeutics. In December 2022 , the WHO released an updated consolidated guideline featuring major improvements on the treatment of drug-resistant TB. The guideline summarizes and recommends the use of a novel all-oral 6-month regimen consisting of pretomanid, bedaquiline, moxifloxacin, and linezolid (BPaLM) for treatment of patients suffering from MDR/RR-TB. The BPaLM regimen is expected to shorten the duration and offer better outcome of treatment.

Furthermore, key players are focusing on collaborations and partnerships to develop novel tuberculosis therapeutics and to maintain their competitive position in the market. For instance, in July 2021 , to advance tuberculosis therapeutics a new consortium of 30 partners from 13 countries has officially launched. The project is UNITE4TB and is a 7-year plan with an investment of around USD 198 million with a goal to accelerate and improve therapeutics. Moreover, initiatives such as the Ni-kshay Mitra launched in September 2022, have come up in India intending to eliminate and target tuberculosis by the end of 2025.

Tuberculosis Therapeutics Market Report Highlights:

• Active TB segment dominated et in 2022 and is attributable to the increasing prevalence and recurrence of condition

• Second line therapy segment is expected to show fastest growth rate over the forecast period owing to increasing demand and the rising research and development for development of newer second-line therapy drugs

• Oral segment dominated the market in 2022 attributable to the availability of a large number of drugs in form of tablets.

• The COVID-19 pandemic influenced the market adversely attributable to the reduced funding for therapeutics and decline in diagnosis rate of disease.

• MEA held the largest market share in 2022 which can be attributed to the enhanced focus on early diagnosis of the disease and improvement in adoption rate of treatments.

Table of Contents

Chapter 1 Tuberculosis Therapeutics Market: Methodology And Scope

• 1.1 Market Segmentation
  • 1.1.1 Segment Scope
  • 1.1.2 Regional Scope
  • 1.1.3 Estimates And Forecast Timeline
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased Database
  • 1.3.2 Gvr's Internal Database
  • 1.3.3 Secondary Sources
  • 1.3.4 Primary Research
  • 1.3.5 Details Of Primary Research
• 1.4 Information Or Data Analysis
  • 1.4.1 Data Analysis Models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity Flow Analysis
    • 1.6.1.1 Approach 1: Commodity Flow Approach
    • 1.6.1.2 Approach 2: Country Wise Market Estimation Using Bottom Up Approach
    • 1.6.1.3 Approach 2: Country Wise Market Estimation Using Top Down Approach
• 1.7 Global Market: Cagr Calculation
• 1.8 List Of Secondary Sources
• 1.9 Objectives
  • 1.9.1 Objective 1
  • 1.9.2 Objective 2
• 1.11 List of Abbreviations

Chapter 2 Tuberculosis Therapeutics Market: Executive Summary

• 2.1 Market Snapshot
• 2.2 Segment Snapshot
• 2.3 Competitive Landscape Snapshot

Chapter 3 Tuberculosis Therapeutics Market: Industry Outlook

• 3.1 Market Lineage Outlook
  • 3.1.1 Parent Market Lineage Outlook
  • 3.1.2 Related/Ancillary Market Outlook
• 3.2 Penetration & Growth Prospect Mapping
• 3.3 Market Dynamics
  • 3.3.1 Market Drivers
    • 3.3.1.1 Rise in the prevalence of tuberculosis
    • 3.3.1.2 Increasing investment for healthcare infrastructure
    • 3.3.1.3 Growing number of geriatric population
  • 3.3.2 Market Restraint Analysis
    • 3.3.2.1 High cost of multidrug-resistant TB
    • 3.3.2.2 Side effects linked with anti-tuberculosis drugs
• 3.4 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• 3.5 Industry Analysis - Porter's
• 3.6 Reimbursement & Regulatory Scenario
• 3.7 Major Deals & Strategic Alliances
  • 3.7.1 New Product Launch
  • 3.7.2 Acquisition
  • 3.7.3 Expansion
  • 3.7.4 Partnerships
  • 3.7.5 Marketing & Promotions

Chapter 4 Tuberculosis Therapeutics Market: Competitive Landscape

• 4.1 Recent Developments & Impact Analysis, By Key Market Participants
  • 4.1.1 Ansoff Matrix
• 4.2 Company Categorization
  • 4.2.1 Innovators
    • 4.2.1.1 Market Differentiators
• 4.3 Vendor Landscape
  • 4.3.1 List Of Key Distributors And Channel Partners
  • 4.3.2 Key Customers
  • 4.3.3 Key Company Market Share Analysis, 2022
• 4.4 Public Companies
  • 4.4.1 Competitive Dashboard Analysis
• 4.5 Private Companies
  • 4.5.1 List Of Key Emerging Companies
• 4.6 Regional Network Map

Chapter 5 Tuberculosis Therapeutics Market: Disease Type Business Analysis

• 5.1 Definition And Scope
• 5.2 Disease Type Market Share Analysis, 2022 & 2030
• 5.3 Global Tuberculosis Therapeutics Market, By Disease Type, 2018 To 2030
• 5.4 Tuberculosis Therapeutics Market: Disease Type Movement Analysis
• 5.5 Active Tb
  • 5.5.1 Active Tb Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.6 Latent Tb
  • 5.6.1 Latent Tb Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6 Tuberculosis Therapeutics Market: Therapy Business Analysis

• 6.1 Definition and Scope
• 6.2 Therapy Market Share Analysis, 2022 & 2030
• 6.3 Global Tuberculosis Therapeutics Market, By Therapy, 2018 To 2030
• 6.4 Tuberculosis Therapeutics Market: Therapy Movement Analysis
• 6.5 First-Line Therapy
  • 6.5.1 First-Line Therapy Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 6.6 Second-Line Therapy
  • 6.6.1 Second-Line Therapy Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 7 Tuberculosis Therapeutics Market: Route of Administration Business Analysis

• 7.1 Definition and Scope
• 7.2 Route of Administration Market Share Analysis, 2022 & 2030
• 7.3 Global Tuberculosis Therapeutics Market, By Route of Administration, 2018 To 2030
• 7.4 Tuberculosis Therapeutics Market: Route of Administration Movement Analysis
• 7.5 Oral
  • 7.5.1 Oral Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 7.6 Parentral
  • 7.6.1 Parentral Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 7.7 Others
  • 7.7.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 8 Tuberculosis Therapeutics Market: Dosage Form Business Analysis

• 8.1 Definition and Scope
• 8.2 Dosage Form Market Share Analysis, 2022 & 2030
• 8.3 Global Tuberculosis Therapeutics Market, By Dosage Form, 2018 To 2030
• 8.4 Tuberculosis Therapeutics Market: Dosage Form Movement Analysis
• 8.5 Tablets
  • 8.5.1 Tablets Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 8.6 Capsules
  • 8.6.1 Capsules Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 8.7 Injections
  • 8.7.1 Injections Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 8.8 Others
  • 8.8.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 9 Tuberculosis Therapeutics Market: Distribution Channel Business Analysis

• 9.1 Definition and Scope
• 9.2 Distribution Channel Market Share Analysis, 2022 & 2030
• 9.3 Global Tuberculosis Therapeutics Market, By Distribution Channel, 2018 To 2030
• 9.4 Tuberculosis Therapeutics Market: Distribution Channel Movement Analysis
• 9.5 Hospital Pharmacy
  • 9.5.1 Hospital Pharmacy Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 9.6 Retail Pharmacy
  • 9.6.1 Reatail Pharmacy Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 9.7 Online Pharmacy
  • 9.7.1 Online Pharmacy Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 9.8 Others
  • 9.8.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 10 Tuberculosis Therapeutics Market: Regional Business Analysis

• 10.1 Definition & Scope
• 10.2 Regional Market Share Analysis, 2022 & 2030
• 10.3 Regional Market Dashboard
• 10.4 Regional Market Snapshot
• 10.5 SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
  • 10.5.1 North America
  • 10.5.2 Europe
  • 10.5.3 Asia Pacific
  • 10.5.4 Latin America
  • 10.5.5 Mea
• 10.6 Market Size, & Forecasts, Trend Analysis, 2022 to 2030
• 10.7 North America
  • 10.7.1 North America Tuberculosis Therapeutics Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 10.7.2 U.S.
    • 10.7.2.1 U.S. Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.7.2.2 Key Country Dynamics
    • 10.7.2.3 Regulatory Framework
    • 10.7.2.4 Competitive Scenario
    • 10.7.2.5 Import Export Scenario
    • 10.7.2.6 Investments Scenario
  • 10.7.3 Canada
    • 10.7.3.1 Canada tuberculosis therapeutics market, 2018 - 2030 (USD Million)
    • 10.7.3.2 Key Country Dynamics
    • 10.7.3.3 Regulatory Framework
    • 10.7.3.4 Competitive Scenario
    • 10.7.3.5 Import Export Scenario
    • 10.7.3.6 Investments Scenario
• 10.8 Europe
  • 10.8.1 Europe Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
  • 10.8.2 U.K.
    • 10.8.2.1 U.K. Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.8.2.2 Key Country Dynamics
    • 10.8.2.3 Regulatory Framework
    • 10.8.2.4 Competitive Scenario
    • 10.8.2.5 Import Export Scenario
    • 10.8.2.6 Investments Scenario
  • 10.8.3 Germany
    • 10.8.3.1 Germany Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.8.3.2 Key Country Dynamics
    • 10.8.3.3 Regulatory Framework
    • 10.8.3.4 Competitive Scenario
    • 10.8.3.5 Import Export Scenario
    • 10.8.3.6 Investments Scenario
  • 10.8.4 Spain
    • 10.8.4.1 Spain tuberculosis therapeutics market, 2018 - 2030 (USD Million)
    • 10.8.4.2 Key Country Dynamics
    • 10.8.4.3 Regulatory Framework
    • 10.8.4.4 Competitive Scenario
    • 10.8.4.5 Import Export Scenario
    • 10.8.4.6 Investments Scenario
  • 10.8.5 France
    • 10.8.5.1 France tuberculosis therapeutics market, 2018 - 2030 (USD Million)
    • 10.8.5.2 Key Country Dynamics
    • 10.8.5.3 Regulatory Framework
    • 10.8.5.4 Competitive Scenario
    • 10.8.5.5 Import Export Scenario
    • 10.8.5.6 Investments Scenario
  • 10.8.6 Italy
    • 10.8.6.1 Italy tuberculosis therapeutics market, 2018 - 2030 (USD Million)
    • 10.8.6.2 Key Country Dynamics
    • 10.8.6.3 Regulatory Framework
    • 10.8.6.4 Competitive Scenario
    • 10.8.6.5 Import Export Scenario
    • 10.8.6.6 Investments Scenario
  • 10.8.7 Russia
    • 10.8.7.1 Russia tuberculosis therapeutics market, 2018 - 2030 (USD Million)
    • 10.8.7.3 Regulatory Framework
    • 10.8.7.4 Competitive Scenario
    • 10.8.7.5 Import Export Scenario
    • 10.8.7.6 Investments Scenario
  • 10.8.8 Denmark
    • 10.8.8.1 Denmark Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.8.8.2 Key Country Dynamics
    • 10.8.8.3 Regulatory Framework
    • 10.8.8.4 Competitive Scenario
    • 10.8.8.5 Import Export Scenario
    • 10.8.8.6 Investments Scenario
  • 10.8.9 Sweden
    • 10.8.9.1 Sweden Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.8.9.2 Key Country Dynamics
    • 10.8.9.3 Regulatory Framework
    • 10.8.9.4 Competitive Scenario
    • 10.8.9.5 Import Export Scenario
    • 10.8.9.6 Investments Scenario
  • 10.8.10 Norway
    • 10.8.10.1 Norway Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.8.10.2 Key Country Dynamics
    • 10.8.10.3 Regulatory Framework
    • 10.8.10.4 Competitive Scenario
    • 10.8.10.5 Import Export Scenario
    • 10.8.10.6 Investments Scenario
• 10.9 Asia Pacific
  • 10.9.1 Asia-Pacific Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
  • 10.9.2 Japan
    • 10.9.2.1 Japan Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.9.2.2 Key Country Dynamics
    • 10.9.2.3 Regulatory Framework
    • 10.9.2.4 Competitive Scenario
    • 10.9.2.5 Import Export Scenario
    • 10.9.2.6 Investments Scenario
  • 10.9.3 China
    • 10.9.3.1 China Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.9.3.2 Key Country Dynamics
    • 10.9.3.3 Regulatory Framework
    • 10.9.3.4 Competitive Scenario
    • 10.9.3.5 Import Export Scenario
    • 10.9.3.6 Investments Scenario
  • 10.9.4 India
    • 10.9.4.1 India Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.9.4.2 Key Country Dynamics
    • 10.9.4.3 Regulatory Framework
    • 10.9.4.4 Competitive Scenario
    • 10.9.4.5 Import Export Scenario
    • 10.9.4.6 Investments Scenario
  • 10.9.5 South Korea
    • 10.9.5.1 South Korea Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.9.5.2 Key Country Dynamics
    • 10.9.5.3 Regulatory Framework
    • 10.9.5.4 Competitive Scenario
    • 10.9.5.5 Import Export Scenario
    • 10.9.5.6 Investments Scenario
  • 10.9.6 Thailand
    • 10.9.6.1 Thailand Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.9.6.2 Key Country Dynamics
    • 10.9.6.3 Regulatory Framework
    • 10.9.6.4 Competitive Scenario
    • 10.9.6.5 Import Export Scenario
    • 10.9.6.6 Investments Scenario
  • 10.9.7 Australia
    • 10.9.7.1 Australia tuberculosis therapeutics market, 2018 - 2030 (USD Million)
    • 10.9.7.2 Key Country Dynamics
    • 10.9.7.3 Regulatory Framework
    • 10.9.7.4 Competitive Scenario
    • 10.9.7.5 Import Export Scenario
    • 10.9.7.6 Investments Scenario
• 10.10 Latin America
  • 10.10.1 Latin America Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
  • 10.10.2 Brazil
    • 10.10.2.1 Brazil Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.10.2.2 Key Country Dynamics
    • 10.10.2.3 Regulatory Framework
    • 10.10.2.4 Competitive Scenario
    • 10.10.2.5 Import Export Scenario
    • 10.10.2.6 Investments Scenario
  • 10.10.3 Mexico
    • 10.10.3.1 Mexico Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.10.3.2 Key Country Dynamics
    • 10.10.3.3 Regulatory Framework
    • 10.10.3.4 Competitive Scenario
    • 10.10.3.5 Import Export Scenario
    • 10.10.3.6 Investments Scenario
  • 10.10.4 Argentina
    • 10.10.4.1 Argentina Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.10.4.2 Key Country Dynamics
    • 10.10.4.3 Regulatory Framework
    • 10.10.4.4 Competitive Scenario
    • 10.10.4.5 Import Export Scenario
    • 10.10.4.6 Investments Scenario
• 10.11 MEA
  • 10.11.1 MEA Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
  • 10.11.2 South Africa
    • 10.11.2.1 South Africa Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.11.2.2 Key Country Dynamics
    • 10.11.2.3 Regulatory Framework
    • 10.11.2.4 Competitive Scenario
    • 10.11.2.5 Import Export Scenario
    • 10.11.2.6 Investments Scenario
  • 10.11.3 Saudi Arabia
    • 10.11.3.1 Saudi Arabia Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.11.3.2 Key Country Dynamics
    • 10.11.3.3 Regulatory Framework
    • 10.11.3.4 Competitive Scenario
    • 10.11.3.5 Import Export Scenario
    • 10.11.3.6 Investments Scenario
  • 10.11.4 UAE
    • 10.11.4.1 UAE Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.11.4.2 Key Country Dynamics
    • 10.11.4.3 Regulatory Framework
    • 10.11.4.4 Competitive Scenario
    • 10.11.4.5 Import Export Scenario
    • 10.11.4.6 Investments Scenario
  • 10.11.5 Kuwait
    • 10.11.5.1 Kuwait Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.11.5.2 Key Country Dynamics
    • 10.11.5.3 Regulatory Framework
    • 10.11.5.4 Competitive Scenario
    • 10.11.5.5 Import Export Scenario
    • 10.11.5.6 Investments Scenario

Chapter 11 Tuberculosis Therapeutics Market: Company Profiling

• 11.1 Company Profiles
  • 11.1.1 Astrazeneca
    • 11.1.1.1 Company Overview
    • 11.1.1.2 Financial Performance
    • 11.1.1.3 Product Benchmarking
    • 11.1.1.4 Strategic Initiatives
  • 11.1.2 Johnson & Johnson Services, Inc.
    • 11.1.2.1 Company Overview
  • 11.1.2 2.Financial Performance
    • 11.1.2.3 Product Benchmarking
    • 11.1.2.4 Strategic Initiatives
  • 11.1.3 Eli Lilly And Company
    • 11.1.3.1 Company Overview
    • 11.1.3.2 Financial Performance
    • 11.1.3.3 Product Benchmarking
    • 11.1.3.4 Strategic Initiatives
  • 11.1.4 F. Hoffmann-La Roche Ltd.
    • 11.1.4.1 Company Overview
    • 11.1.4.2 Financial Performance
    • 11.1.4.3 Product Benchmarking
    • 11.1.4.4 Strategic Initiatives
  • 11.1.5 Viatris Inc. (Mylan N.V.)
    • 11.1.5.1 Company Overview
    • 11.1.5.2 Financial Performance
    • 11.1.5.3 Product Benchmarking
    • 11.1.5.4 Strategic Initiatives
  • 11.1.6 Teva Pharmaceutical Industries, Ltd.
    • 11.1.6.1 Company Overview
    • 11.1.6.2 Financial Performance
    • 11.1.6.3 Product Benchmarking
    • 11.1.6.4 Strategic Initiatives
  • 11.1.7 Sanofi
    • 11.1.7.1 Company Overview
    • 11.1.7.2 Financial Performance
    • 11.1.7.3 Product Benchmarking
    • 11.1.7.4 Strategic Initiatives
  • 11.1.8 Novartis Ag
    • 11.1.8.1 Company Overview
    • 11.1.8.2 Financial Performance
    • 11.1.8.3 Product Benchmarking
    • 11.1.8.4 Strategic Initiatives
  • 11.1.9 Sun Pharmaceutical Industries Ltd.
    • 11.1.9.1 Company Overview
    • 11.1.9.2 Financial Performance
    • 11.1.9.3 Product Benchmarking
    • 11.1.9.4 Strategic Initiatives
  • 11.1.10 Pfizer Inc.
    • 11.1.10.1 Company Overview
    • 11.1.10.2 Financial Performance
    • 11.1.10.3 Product Benchmarking
    • 11.1.10.4 Strategic Initiatives